New Study Suggests GLP-1 Receptor Agonists Could Target the Brain Pathways Behind Bipolar Disorder

The GLP-1 drugs transforming diabetes and obesity treatment may have a future in mental health. A study published in Molecular Psychiatry proposes that medications like Ozempic and Wegovy (semaglutide) could benefit people with bipolar disorder — not by targeting mood directly, but by acting on the brain and body systems that fuel the illness.

“GLP-1 receptor agonists act on several biological systems that are also disrupted in bipolar disorder,” said Dr. Cristian Llach, a psychiatrist and research fellow at the University of Toronto, who co-authored the study, in an interview with Health Central. “What makes them interesting is not that they target mood directly, but that they influence core brain and body mechanisms that contribute to the illness.”

How GLP-1 Drugs Could Help

The Molecular Psychiatry review identified several pathways through which GLP-1 drugs might affect bipolar disorder. Insulin resistance, which has been linked to greater depressive burden and cognitive impairment in bipolar patients, is one target. GLP-1s improve insulin sensitivity, and since insulin also plays a role in brain function, restoring that signaling could help stabilize mood.

Chronic inflammation is another factor. Both bipolar disorder and insulin resistance are accompanied by low-grade systemic inflammation that worsens treatment outcomes.

“When I started researching GLP-1s for weight loss, I was fascinated because now we have the opportunity to treat upstream the source of the inflammation that is worsening outcomes in mood disorders,” said Dr. Jennifer Kruse, an associate professor of psychiatry at UCLA’s David Geffen School of Medicine.

The drugs may also enhance neuroplasticity — the brain’s ability to adapt and heal — and act on reward-processing pathways involving dopamine, the same circuitry that drives impulsivity and mood instability in bipolar disorder.

Not a Replacement for Mood Stabilizers

Experts are clear: GLP-1 drugs are not a substitute for existing bipolar treatments, and the FDA has not approved them for psychiatric use. A separate 2024 study in Scientific Reports found an association between GLP-1 use and increased risk of depression, anxiety, and suicidal behaviors in people with obesity — though it excluded people with pre-existing psychiatric conditions and did not establish causation.

“Overall, GLP-1 receptor agonists are best viewed as adjunctive treatments that may improve metabolic health, functioning, and certain psychiatric comorbidities, without destabilizing mood,” Dr. Llach said. “Ongoing controlled trials will be essential.”

For people living with bipolar disorder, the metabolic angle is significant. Research published in Frontiers in Psychiatry found that 29 percent of people with bipolar disorder are obese, often worsened by long-term use of mood stabilizers and antipsychotics. If GLP-1 drugs can improve metabolic health without destabilizing mood, they could meaningfully improve quality of life.

A note from Liam Ronan: This one caught my attention because I’m on Ozempic and I’ve been on a mood stabilizers for over a year. Weight gain and insulin resistance has always been an issue for me too. If GLP-1 drugs can help with that while also supporting brain health, that would be awesome

See recent or related posts:
• New Research Points to Lithium Alternative for Treatment-Resistant Bipolar Disorder
• FDA Just Approved a New Drug for Bipolar I — Here’s What You Need to Know
• Researchers Testing ‘Ketogenic-Mimicking’ Plan for Treatment of Mania and Depression
• Review Questions Whether Valproate Should Be First-Line Treatment for Acute Mania
• New Wearable Sensor Could Help Patients with Bipolar Disorder Track Medication